The invention concerns tachykinin antagonists. The compounds are alcohols, amines and prodrugs of nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central ...
Additional Information Licensing Caveats: Sold with the permission of Merck, Sharpe and Dohme Ltd. Product Datasheets COA view current batch Or select another batch: 54321 View Batch SDS Reconstitution Calculator Molarity Calculator mlul mgugng
Tocris products are intended for laboratory research use only, unless stated otherwise. Customers also Viewed Additional Information Licensing Caveats: Sold with the permission of Astellas Pharma Inc. Product Datasheets COA view current batch SDS
The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of ...
ChemInform Abstract: Synthesis of Two Neurokinin NK1 Receptor Antagonists: (+)-L-733,060 and (—)-L-733,061.doi:10.1002/chin.201316212organic chemistry, reviewother bioactive productsAnne CochiLab. Chim. Org., CNRS, Ec. Super. Phys. Chim. Ind., F-75231 Paris, Fr.Domingo Gomez Pardo...
ChemInformDinnell K, Chicchi GG, Dhar MJ, Elliott JM, Hollingwork GJ, Kurtz MM, Ridgill MP, Rycroft W, Tsao K, Williams AR, Swain CJ: 2-Aryl indole NK1 receptor antagonists: optimization of the 2- aryl ring and the indole nitrogen substituent. Bioorg Med Chem Lett 2001, 11:1237-...
Neurokinin 1 (NK1) receptor antagonists are a drug class aimed at treating nausea and vomiting associated with chemotherapy.
Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. Duffy et al. J.Pharmacol.Exp.Ther., 2002;301:536 Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. ...
The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK<HIL>1</HIL>-receptor antagonists, processes for preparing them and their use in the treat
Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. Examples of conditions in which substance P has been implicated include disorders ...